Supporting women with adherence to adjuvant endocrine therapy (SWEET): feasibility study of the HT&Me intervention
European Journal of Oncology Nursing · 2026
DOI: 10.1016/j.ejon.2025.103026 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Oncology Nursing, 2026. Verfasst von Lucy McGeagh und 20 weiteren Autor:innen. Beteiligte Einrichtung: Oxford Institute of Applied Health Research, Oxford Brookes University, Oxford, UK. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Agents, Hormonal, Medication Adherence. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Newcastle upon Tyne Hospitals NHS Foundation Trust, National Institute for Health Research Programme Grants for Applied Research, National Institute for Health and Care Research.
Abstract (Originalsprache)
PURPOSE: Women with estrogen receptor-positive breast cancer are recommended daily oral adjuvant endocrine therapy for at least 5 years, but up to 50 % discontinue early. We assessed an evidence-based, theoretically-informed, patient-centred intervention (HT&Me) to support adjuvant endocrine therapy adherence and improve quality-of-life, in terms of patient acceptability and feasibility to deliver within the UK National Health Service. METHODS: This single arm study aimed to recruit 45 women with stage I-III breast cancer within 14 weeks of first adjuvant endocrine therapy prescription. After completing baseline questionnaires, participants received the HT&Me intervention comprising: (i) a short animation; (ii) two personalised nurse/practitioner consultations (in-person or online); (iii) an interactive web-app; and (iv) regular email reminders. Participants completed follow-up questionnaires at 8 weeks. A sub-sample of participants (n = 20) and health professionals (n = 14) participated in semi-structured interviews. RESULTS: We recruited 51 participants. Participants varied in digital confidence at recruitment (low/moderate, 28 % (n = 14); high, 61 % (n = 31)). HT&Me was demonstrated as feasible to deliver. Overall, 69 % (n = 35) engaged with the web-app; 87 % (n = 40/46) found HT&Me helpful; and 80 % (n = 36/45) reported it motivated them to keep taking endocrine therapy. Both consultation formats were considered acceptable. Completion of outcome measures was high. Health professionals considered HT&Me addresses an important unmet need. CONCLUSIONS: HT&Me is feasible, acceptable and helpful to women. Findings provided valuable insights for design and delivery of the full-scale randomised controlled trial assessing effectiveness now underway (ISRCTN24852890). HT&Me offers potential to improve adjuvant endocrine therapy adherence, thereby reducing recurrence risk for women with estrogen receptor positive breast cancer. STUDY REGISTRATION ISRCTN NUMBER: ISRCTN29401613.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oxford Institute of Applied Health Research, Oxford Brookes University, Oxford, UK.
- Research Department of Practice and Policy, UCL School of Pharmacy, University College London, London, UK.
- Population Health Sciences Institute, Newcastle University, Newcastle, UK.
- Imperial College Healthcare NHS Trust, London, UK; Imperial College London, London, UK.
- Translational and Clinical Research Institute, Newcastle University, Newcastle, UK.
- Research Software Engineering, Newcastle University, Newcastle, UK.
Förderung
- Newcastle upon Tyne Hospitals NHS Foundation Trust
- National Institute for Health Research Programme Grants for Applied Research
- National Institute for Health and Care Research
Zitieren
APA
McGeagh, L., Stewart, S. J., Norris, R., Wells, M., Thompson, S., Mawson, P., Brett, J., Turner, M., Wolstenholme, J., Dakin, H., Donnelly, P., Cain, H., Rehman, F., Kum, S., Horne, R., Taylor, G., Turner, L., Rose, J., Sharp, L., …, & SWEET Research Team (2026). Supporting women with adherence to adjuvant endocrine therapy (SWEET): feasibility study of the HT&Me intervention. European Journal of Oncology Nursing. https://doi.org/10.1016/j.ejon.2025.103026
Vancouver
McGeagh L, Stewart SJ, Norris R, Wells M, Thompson S, Mawson P, et al. Supporting women with adherence to adjuvant endocrine therapy (SWEET): feasibility study of the HT&Me intervention. European Journal of Oncology Nursing. 2026. doi:10.1016/j.ejon.2025.103026
BibTeX
@article{McGeagh2026,
author = {McGeagh, Lucy and Stewart, Sarah-Jane and Norris, Ruth and Wells, Mary and Thompson, Sue and Mawson, Phil and Brett, Jo and Turner, Mark and Wolstenholme, Jane and Dakin, Helen and Donnelly, Peter and Cain, Henry and Rehman, Farah and Kum, Sally and Horne, Rob and Taylor, Guy and Turner, Lesley and Rose, Jan and Sharp, Linda and Watson, Eila and SWEET Research Team, SWEET Research Team},
title = {Supporting women with adherence to adjuvant endocrine therapy (SWEET): feasibility study of the HT&Me intervention},
journal = {European Journal of Oncology Nursing},
year = {2026},
doi = {10.1016/j.ejon.2025.103026}
}
EUVIMED